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• Antibodies can develop during the course of epilepsy and are not likely to be the sole cause of epilepsy in pediatric patients
• However, if associated with clinical features suggestive of autoimmune encephalitis, this "secondary inflammation" may be immunotherapy responsive as seen in other antibody-mediated diseases In adults, autoantibodies to essential neuronal proteins such as the N-methyl-D-aspartate receptor (NMDAR) and the voltage gated potassium channel (VGKC)-complex antigen, leucine rich glioma inactivated 1 (leucine rich glioma inactivated 1 (LGI1), are now widely recognized as an important treatable cause of encephalitis. 1, 2 Patients present with memory loss, confusion, and seizures in limbic encephalitis with predominantly LGI1 antibodies 3, 4 and neuropsychiatric features, movement, and autonomic symptoms in NMDAR-Ab (antibody) encephalitis. 5, 6 However, the recent characterization of faciobrachial dystonic seizures (FBDS) in patients with LGI1 antibodies has widened the phenotype to include patients presenting with seizure predominance. 7, 8 Recognition of each of these diseases is important, as they are responsive to immunotherapies.
In adult and pediatric patients with epilepsy or seizures without encephalitis, autoantibodies are present in approximately 9-13%. [9] [10] [11] [12] These patients are more likely to have been classified as "focal epilepsy of unknown cause" and show a tendency toward standard antiepileptic drug (AED) resistance. 11, 12 However, in these studies, followup was short, and immunologic treatments have been tried on an empirical basis at a time when the presence of an antibody was unknown. With increasing interest in the possible etiologic role of autoantibodies in epilepsy, and the recognition that early diagnosis and immunotherapy treatment improves outcome in autoimmune encephalitis, it is important for the clinician to be able to make informed decisions regarding which patients to test and whether the results will affect patient management and epilepsy outcome. 13, 14 Here we studied archived samples from patients who had been sampled within a median 69 days from their first presentation to the neurologist and followed up for many years. None of the patients were given immunotherapies and some were resampled at 6 and 12 months. The results were compared with age-and sex-matched healthy controls.
Methods

Patient cohort
Children (aged 1 month to 16 years) were enrolled into the Dutch Study of Epilepsy in Childhood (DSEC) from four participating centers in The Netherlands between 1988 and 1992. Details of exclusion and inclusion criteria have been published previously. 15, 16 Children with a presumed "acute symptomatic" etiology for their epilepsy (defined as seizures occurring only during the first week after the onset of acute neurologic insult, for example, stroke, head trauma, or central nervous system infection, or concurrently with an acute systemic metabolic disturbance, for example, uremia, hyponatremia, or hypoglycemia, or both. 17 ) were excluded.
Sufficient volumes of serum were available only in 178 children at enrollment (out of the total cohort of 881 patients who were enrolled and discussed). The median period between the first seizure and first blood sampling was 69 days (range 0 days to 6.4 years). All of the serum samples were stored at À20°C from collection. A previous study by the DSEC found no significant differences in sex, etiology, or epilepsy syndrome between those children with available samples and those without. 18 Follow-up serum samples from 96 patients taken at 6 months (n = 30), 12 months (n = 34), and 6 and 12 months (n = 32) after intake were also available for testing. In addition, 112 age and sex-matched control samples came from age-matched sibling donors of bone marrow transplantations (BMTs), collected between 1985 and 1995 and stored under the same condition as the patients' sera.
Ethics
The DSEC was approved by the ethics committees of all involved hospitals, and informed consent was obtained in all cases before enrollment. 15, 19 Epilepsy classification and definitions
At enrollment, classification of the seizures and epilepsy syndromes was made after discussion by three participating pediatric neurologists according to the 1989 International League Against Epilepsy (ILAE) criteria. This was revised after 2 years and at the end of the most recent intractability study, 20 as some children proved to have neurologic brain-related morbidities. In view of the new terminology published in the most recent reorganization of the ILAE seizure and epilepsy classification, and to facilitate interpretation of the new serologic data with the preexisting clinical data, we have provided definitions of the terms used in Table 1 .
Antibody testing of serum samples
Antibodies to the VGKC complex and to the intracellular enzyme glutamic acid decarboxylase (GAD) were measured by radioimmunoassays. To avoid reporting results of low specificity, 21, 22 VGKC-complex antibody positivity was set at >400 pM and GAD positivity at >100 units/ml. 11 Cellbased assays (CBAs) were used to detect antibodies to the NMDAR, alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), LGI1, CASPR2, and contactin-2. These tests were scored on a visual scale: 0, no binding; 1, low but specific binding; to 4, strong binding to all transfected cells by two independent observers as previously described 3, 5 and in use for routine diagnostics. All positive samples were confirmed, and then tested blind by LW as part of a routine antibody service, with dilutions to assess the titer; the positives samples were also tested for binding to the surface of live hippocampal neurons in culture, prepared from P0 Sprague-Dawley rat pups as described previously.
23,24
Statistical analysis
Descriptive statistics were used to summarize patient data. Fisher's exact test was used to compare categorical data. Data were analyzed using GraphPad Prism 6.0.
Results
Autoantibody testing
Seventeen patients (17/178; 9.5%) were positive for one antibody (VGKC complex Table 2 ). Antibodies to LGI1, AMPAR, or GAD were not identified in any patients or controls. Although antibodies binding to the cell-surface antigens were not high (scoring 1 at dilution 1:20 in 5 and at dilution 1:100 in 9), eight of these samples bound to the surface of live hippocampal neurons (see Table 2 ), which suggests potential clinical relevance.
Clinical features of antibody positive patients
The clinical and paraclinical features, treatment responses, and outcomes of the antibody-positive patients are listed in Table 2 . All three patients with VGKC complex Abs had cognitive impairment/learning difficulties (this was not present in the VGKC complex antibody-positive healthy control). The two patients (cases 1 and 2; Table 2 ) with the highest titers (712, 480 pM) had focal epilepsy that was difficult to treat, needing at least three AEDs for seizure control initially. Although there were no antibodies detected to the VGKC-complex-associated proteins, LGI1 and CASPR2 in these samples, both bound to the surface of hippocampal neurons suggesting potential clinical relevance.
Three of the seven NMDAR-Ab-positive patients had learning difficulties before the onset of epilepsy (cases 6-8), including one severely affected (case 7), and required Epilepsies considered the consequence of a known or suspected disorder of the central nervous system resulting in a static encephalopathy. All children with mental retardation (MR) with epilepsy of unknown cause were classified as RSE Cryptogenic epilepsy (CE)
Epilepsies of unknown origin that do not conform to the criteria for IE or RSE Terminal remission
Interval between the very last seizure and the end of follow-up Fast response to medication 6 Months of remission starting within 2 months after initiation of AED
Intractability
No remission exceeding 3 months (at least one seizure per 3 months) during a minimum period of 1 year of observation despite adequate treatment. 16 AEDs until the end of follow-up. Three others (cases 4, 5, and 9) had childhood absence epilepsy with 3-Hz generalized spike-wave discharge on electroencephalography (EEG). Three patients were positive for contactin-2 antibodies (cases 11-13); two were known to be on the autistic spectrum and one had pharmacoresistant benign epilepsy with centrotemporal spikes (BECTS) requiring three AEDs for seizure control. Four patients were positive for CASPR2 antibodies; two (cases 16, 17) had focal epilepsy with periods of resistance to AEDs.
Comparison of clinical features and long-term outcomes between antibody-positive and antibody-negative patients There were no differences in the sex distribution or age at onset of epilepsy between antibody-positive and antibody-negative patients. Seizure semiology and frequency also showed no long-term difference, and computed tomography (CT) and EEG findings were comparable (Table 3) . Overall, however, there was a significantly higher rate of cognitive impairment/developmental delay in the antibody-positive patient group (9/17 vs. 33/161; p = 0.01). These features were all present before the onset of epilepsy (and hence antibody testing), and included patients with structural brain abnormalities, mild autism, and severe global development delay.
At 5-year follow-up, 65% (11/17) of patients in the antibody-positive and 78% (125/161) in the antibody negative group had been seizure-free for >12 months (not significant). At final contact, 57% (8/14) of the antibody-positive patients were taking AEDs compared to 31% (44/140) of antibody-negative patients (p = 0.07, Table 3 ), but the rate of intractability was not different between the two groups (p = 0.18, Fisher's exact test).
Testing of follow-up samples
Of the 17 patients who were antibody positive at intake, further samples at 6 and 12 months were available for antibody testing in 7 (Fig. 1H,I ). Changes in these short-term antibody levels (Fig. 1H,I ) did not correlate with changes in seizure frequency or cognitive development (Table 2) . Moreover, 7 (7.7%) of 89 sera from patients who had been antibody negative (n = 161) were found to be positive at follow-up (NMDAR-Abs [n = 3], CASPR2-Abs [n = 2], CASPR2-and NMDAR-Abs [n = 1], and contactin-2-Abs [n = 1]). Two of these patients became intractable in the long-term (cases 27 and 64). The antibodies and clinical features of these patients are listed in Table S1 . When available, follow-up samples were tested; four of five NMDAR-Ab positive patients and both VGKC-complex antibody-positive patients were negative at either 6 or 12 months after intake (H, I). Patient 4 showed an initial reduction in antibody levels then increase over time. These fluctuating antibody levels did not correlate with developmental regression or seizure activity. Epilepsia ILAE 
Discussion
Autoantibodies to neuronal surface antigens have been reported in adults and children with epilepsy and could indicate an immune basis with obvious management implications. [11] [12] [13] However, these studies have been complicated by some use of immunotherapies, and long-term treatment and outcome data of untreated antibody-positive patients have not been reported. We were able to test a large, historical cohort of patients with pediatric epilepsy for neuronal surface antibodies and relate the findings to their epilepsy course over time. The frequency of antibodies were similar to those reported previously, but were mainly transient and occurred sporadically; despite lack of immunotherapies, most autoantibody positive patients had a good outcome and responded to standard AEDs. The results suggest, therefore, that routine antibody testing is not necessarily helpful in children with epilepsy and should be restricted to those with evidence of neuroinflammatory disease. Nevertheless, the number of patients (n = 11) who had or developed antibodies to CASPR2 or contactin-2, proteins that are linked to genetic forms of epilepsy or neurodevelopmental disorders, is an intriguing finding that deserves further study.
The frequency of antibody positivity in this study cohort (9.5% compared with 2.6% in controls) was similar to that published previously for both adult and pediatric epilepsies (10-16% in patients and <5% in controls). Patients with acute symptomatic epilepsy had been excluded and, importantly, the patients did not have any associated clinical features of encephalitis (e.g., confusion, memory loss) at the time of sampling, and none had received immunotherapies. All cell-based assay-positive samples obtained at onset contained relatively low antibody titers, 8/14 bound to the surface of hippocampal neurons in vitro, and most available follow-up samples had normalized by 12 months, whereas antibodies had appeared de novo in seven patients. Although samples were taken as close to seizure onset as possible, the median sampling time of 69 days means that some were taken after the establishment of epilepsy and the results could, therefore, reflect the consequences of the epileptogenic process rather than being the primary cause. Indeed, low-titer antibodies to VGKC complex or NMDARs have been found in some patients without autoimmune neurologic diseases, 21, 25 and the fact that NMDARs were found in some children with generalized absence epilepsy makes them unlikely to be pathogenic in these cases. However, the binding to the surface of live hippocampal neurons, present in 8 of 17 sera, suggested that the antibodies could be pathogenic if they reach the brain parenchyma. In the remaining patients whose antibodies did not bind to the neurons or to LGI1, the VGKC-complex Abs may be markers for a neuroinflammatory process rather than for an antibody-mediated syndrome, as recently discussed. 12, 22, 26 Surprisingly, therefore, antibodies to CASPR2 or contactin-2, the other known components of the VGKC complex, were found in 11 pediatric epilepsy patients (seven at onset, four during follow-up), but not in controls. This finding draws attention to the growing area of shared targets and partially overlapping phenotypes between antibody and genetic forms of pediatric neurologic disease. 12, 27 Despite the limitations of a retrospective study with no access to cerebrospinal fluid (CSF) samples for testing, this observational study enabled us to investigate the long-term outcome of antibody positivity in a cohort of patients with pediatric epilepsy in whom immunotherapies were not used. Because most patients responded well to standard AEDs and had a good long-term outcome, this questions the pathologic relevance of these low positive antibodies particularly as, in most cases, the antibodies were transient and disappeared by 6 or 12 months follow-up. It seems likely that the antibodies may have been a secondary response to neuronal damage before the seizures came under control, rather than the primary pathogenic agent. Nevertheless, this is not unprecedented and the development of high levels of NMDAR-Abs following herpes simplex virus encephalitis (HSVE) with neurologic deterioration (movement disorder, behavioral change, seizures, and worsening of brain lesions on magnetic resonance imaging [MRI] ), in patients with no evidence of reactivation of the herpes simplex virus, 28 and their response to immunotherapy, 29 demonstrates that this "secondary inflammation" may still be pathogenic and respond to immunotherapy.
From these results, a "mono-immunogenic" cause for pediatric epilepsy is unlikely, with neuronal antibodies forming only part of the complex etiologic framework that includes inflammation, structural abnormalities, and genetic susceptibility; similar diverse factors may explain the final outcomes. Future studies investigating predictive biomarkers in epilepsy need to include all these factors to indicate the likely progression of disease and treatment response. This would be invaluable to both patients and clinicians, 30 particularly in drug-resistant refractory cases with associated comorbidities, commonly seen in pediatric epilepsy. This group of patients may benefit most from further studies into antibody presence, antigenic targets, relevance, and immunotherapy treatment trials.
